8-K
filed February 27, 2024, 6:59 PM ET
ticker MASI
CIK 0000937556
earnings
confidence high
sentiment positive
materiality 0.75
Masimo Q4 revenue $548.9M, GAAP EPS $0.63; full-year $2,048.1M; FY2024 guidance $2,045-2,165M
MASIMO CORP
2023-FY EPS reported
$1.51
revenue$2,048,100,000
- Q4 consolidated revenue $548.9M (healthcare $339.9M, non-healthcare $209.0M).
- GAAP EPS $0.63; non-GAAP EPS (updated) $1.25.
- Full-year 2023 revenue $2,048.1M; GAAP EPS $1.51; non-GAAP EPS $3.79.
- Q1 2024 guidance: revenue $476-501M; full-year 2024 revenue $2,045-2,165M.
- CEO cites record contract wins, FDA clearances, and hearables growth as momentum drivers.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
MASIMO CORP reported Full-Year 2023 results: revenue $2,048.1 million, net income $81.5 million, EPS $1.51.
- Period
- Full-Year 2023
- Revenue
- $2,048.1 million
- Net income
- $81.5 million
- EPS
- $1.51
- Result
- reported results
Exact text from the filing
Consolidated revenue was $2,048.1 million, consisting of healthcare revenue of $1,275.5 million and non-healthcare revenue of $772.6 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 263,000. Consolidated GAAP operating income was $136.5 million. Consolidated non-GAAP operating income (prior definition) was $269.6 million. Consolidated non-GAAP operating income (updated definition) was $313.0 million. Consolidated GAAP net income was $81.5 million, or $1.51 per diluted share.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
MASIMO CORP reported Fourth Quarter 2023 results: revenue $548.9 million, net income $34.0 million, EPS $0.63.
- Period
- Fourth Quarter 2023
- Revenue
- $548.9 million
- Net income
- $34.0 million
- EPS
- $0.63
- Result
- reported results
Exact text from the filing
Consolidated revenue was $548.9 million, comprised of healthcare revenue of $339.9 million and non-healthcare revenue of $209.0 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,500. Consolidated GAAP operating income was $44.1 million. Consolidated non-GAAP operating income (prior definition) was $78.6 million. Consolidated non-GAAP operating income (updated definition) was $91.7 million. Consolidated GAAP net income was $34.0 million, or $0.63 per diluted share.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.